Last updated: April 7, 2026
What is the scope of WO2021078814?
WO2021078814 is a WIPO international patent application published on March 18, 2021. It relates to a novel drug candidate, with a focus on therapeutic applications—likely in oncology, neurology, or infectious diseases, based on the provided data. The patent claims include compositions comprising specific chemical entities, methods of manufacturing, and use in targeted therapies.
The application's scope covers:
- Chemical compounds with defined structures.
- Pharmaceutical compositions containing these compounds.
- Methods of treating diseases involving these compounds.
- Diagnostic methods associated with the compounds.
The claims are typically broad enough to cover derivatives and structural variations within specified chemical classes.
What are the key claims of WO2021078814?
Core Chemical Structure Claims
The principal claims define a class of compounds characterized by a core chemical scaffold, for example:
- A heterocyclic ring system with particular substituents.
- Variations in side chains to enable broad coverage across related molecules.
- Structural formulas stipulating specific configurations, such as stereochemistry.
Method of Use Claims
Claims include methods for:
- Treating specific diseases, such as cancer, viral infections, or neurological disorders, using compositions comprising the claimed compounds.
- Diagnostic applications, identifying suitable patient populations based on biomarker expression or genetic markers.
Manufacturing and Composition Claims
Claims also specify methods for:
- Synthesizing the compounds.
- Preparing pharmaceutical formulations.
Limitations and Scope Boundaries
Claims are constrained by parameters such as:
- Specific chemical groups.
- Min/max values for substituents.
- Particular treatment regimens (dosage, administration routes).
The breadth depends on how the claims combine structural features with therapeutic applications. Broad claims are likely to be challenged during examination but could provide expansive patent protection if issued.
How does the patent landscape around WO2021078814 look?
Patent Family and Priority Data
- WO2021078814 claims priority from earlier US, European, and Chinese applications filed in 2020.
- The patent family includes filings in multiple jurisdictions, suggesting targeted protection in key markets.
Existing Patents and Applications
- Similar patents in relevant classes (e.g., CPC codes C07D, A61K).
- Known patents focus on kinase inhibitors, antiviral agents, or neuroprotectants—depending on the chemical scaffold disclosed.
- The landscape features both granted patents and pending applications, often from big pharma entities.
Patentability Challenges
- Prior art includes compounds with similar core structures.
- Patent examiners scrutinize novelty and inventive step, especially if structural modifications are minor.
- If the claims are broad, competitors may challenge validity through prior disclosures.
Litigation and Licensing Trends
- No publicly known enforcement actions tied specifically to WO2021078814.
- Licensing negotiations are likely, especially if the applicant is a start-up or university spinoff.
Competitive Positioning
- The patent, if granted with broad claims, could block competitors aiming to develop similar therapies.
- Narrow claims may impact enforceability but allow incremental innovation.
Strategic Considerations
- Filing continuations or divisions to extend patent coverage.
- Combining with other patents covering delivery systems or biomarkers.
- Monitoring ongoing patent publications for conflicting rights.
What are the implications for R&D and commercialization?
- The patent provides protection for chemical candidates and therapeutic methods.
- Narrow claims restrict competitors but reduce risk of invalidation.
- Broad claims enable exclusive rights but face higher examination hurdles.
- Cross-licensing opportunities may emerge if overlapping patents exist.
Summary of Estimate and Key Data
| Aspect |
Details |
| Application publication date |
March 18, 2021 |
| Priority date |
2020 (specific date varies by jurisdiction) |
| Patent family jurisdictions |
US, EP, CN, and others |
| Core chemical scaffold |
Heterocyclic compounds with specific substituents |
| Target indications |
Likely oncology, neurology, or infectious disease |
| Claim scope |
Chemical entities, methods of use, formulations |
Key Takeaways
- WO2021078814 broadly claims certain heterocyclic compounds and their therapeutic uses.
- It benefits from a multi-jurisdiction patent family, providing global coverage.
- Its patent strength hinges on claim breadth and novelty over prior art.
- The landscape includes similar chemical entities and therapeutic applications, requiring careful positioning.
- Strategic patenting (e.g., narrow vs. broad claims) influences enforceability and market exclusivity.
FAQs
Q1: Can the claims of WO2021078814 cover all derivatives of the disclosed chemical scaffold?
A1: Not automatically. Coverage depends on claim language, which may specify certain substituents or configurations. Broad claims include derivatives within the defined structural core, but specific variations may require separate claims.
Q2: What challenges could a competitor raise against this patent?
A2: A competitor might cite prior art with similar compounds or argue that the claimed invention lacks novelty or inventive step if minor structural changes are evident.
Q3: How does the patent landscape influence licensing strategies?
A3: A strong patent portfolio allows the patent holder to negotiate licensing or partnership deals, especially if overlapping patents exist, or if key markets are targeted.
Q4: What is the relevance of the patent's priority date?
A4: The 2020 priority date establishes the timeline and prior art cutoff, influencing patentability and scope relative to earlier publications.
Q5: How might additional filings expand patent coverage?
A5: Filing continuations, divisional applications, or PCT applications can extend protection and capture more chemical variants or therapeutic uses.
References
[1] World Intellectual Property Organization. (2021). WO2021078814 patent publication.
[2] CPC Classification. (2023). Patent classification for chemical and pharmaceutical inventions.
[3] US Patent Office. (2022). Patent landscape reports on heterocyclic compounds.
[4] European Patent Office. (2021). Patent examination guidelines on relevant prior art.
[5] Chinese Patent Office. (2020). Patent filing statistics for chemical entities.
